Ament M E, Vargas J H
Department of Pediatrics, UCLA School of Medicine 90024.
Semin Pediatr Surg. 1994 Feb;3(1):28-32.
Corticosteroids remain the primary therapeutic agent to induce remission in moderate to severe ulcerative colitis (UC) and Crohn's disease because of their rapidity of action in comparison to other agents. Mild UC and/or Crohn's disease of the colon and terminal small bowel may be treated with azulfidine first. However, if patients are intolerant of these medications, dipentum or asacol may be used. Occasionally, patients with Crohn's colitis but not UC may respond to metronidazole. Immunosuppressive agents such as 6-mercaptopurine are very useful for steroid-dependent inflammatory bowel disease, as a substitute for long-term corticosteroids. Cyclosporine, although it has been proposed as an alternative to other antimetabolite or immunosuppressive therapy, is of benefit in fewer than 25% of cases of UC or Crohn's disease. Rowasa enemas are useful for left-sided disease in UC or Crohn's disease of the colon; however, use in children may be difficult in view of psychosocial issues that must be considered.
由于与其他药物相比起效迅速,皮质类固醇仍然是诱导中度至重度溃疡性结肠炎(UC)和克罗恩病缓解的主要治疗药物。轻度UC和/或结肠及末端小肠的克罗恩病可首先用柳氮磺胺吡啶治疗。然而,如果患者对这些药物不耐受,可使用奥沙拉嗪或美沙拉嗪。偶尔,患有克罗恩结肠炎而非UC的患者可能对甲硝唑有反应。免疫抑制剂如6-巯基嘌呤对依赖类固醇的炎症性肠病非常有用,可作为长期皮质类固醇的替代品。环孢素虽然已被提议作为其他抗代谢物或免疫抑制疗法的替代药物,但在不到25%的UC或克罗恩病病例中有益。灌肠剂对UC或结肠克罗恩病的左侧病变有用;然而,考虑到必须考虑的社会心理问题,在儿童中使用可能会有困难。